Back to top
more

Aridis Pharmaceuticals (ARDS)

(Delayed Data from OTC)

$0.06 USD

0.06
5,538

0.00 (1.06%)

Updated May 9, 2024 01:27 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ARDS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Aridis Pharmaceuticals [ARDS]

Reports for Purchase

Showing records 1 - 20 ( 51 total )

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 1

11/06/2023

Company Report

Pages: 5

3Q23: We Believe AR-301 Attractive For Near-Term Partnership Interest; Reiterate Buy and $2 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 2

10/20/2023

Company Report

Pages: 5

Recent Regulatory Developments Are Positive For AR-301; Reiterate Buy With a New $2 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 3

01/26/2023

Company Report

Pages: 5

AR-301 Phase 3 Study Shows Positive Trends; Reiterate Buy With PT Adjusted to $10

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 4

12/12/2022

Daily Note

Pages: 3

Investment From the Cystic Fibrosis Foundation to Support AR-501 Development; Reiterate Buy Rating and $19 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 5

12/08/2022

Company Report

Pages: 5

KOL Event Highlights the Need for a Therapy Like AR-301; Reiterate Buy and $19 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 6

11/23/2022

Company Report

Pages: 5

AR-301 Phase 3 On-Track for Top-line Data in December; Reiterate Buy and $19

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 7

11/23/2022

Daily Note

Pages: 3

AR-301 and Immune-Based Approaches to Treating Infectious Diseases

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 8

08/22/2022

Company Report

Pages: 5

AR-301 Phase 3 and AR-501 Phase 2a Top-Line Data on Track for 2H22; Reiterate Buy and $19 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 9

06/07/2022

Company Report

Pages: 5

Expecting Top-Line AR-301 Phase 3 Data and Multiple Readouts in 2H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 10

04/05/2022

Company Report

Pages: 4

Expecting Top-Line AR-301 Phase 3 Data in 2H22; Reiterate Buy and $19 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 11

02/17/2022

Daily Note

Pages: 3

Pan-Coronavirus Monoclonal Antibody Approach Protective Against Omicron and Delta; Reiterate Buy and $19 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 12

01/27/2022

Daily Note

Pages: 3

Funding From the Bill and Melinda Gates Foundation; Reiterate Buy and $19 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 13

12/29/2021

Daily Note

Pages: 3

AR-701 Effective Against Omicron; Reiterate Buy Rating and $19 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 14

11/11/2021

Company Report

Pages: 4

Expecting AR-320 to be Complementary to AR-301; Reiterate Buy Rating and $19 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 15

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ARDS

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 16

07/20/2021

Company Report

Pages: 5

In-Licensing of AR-320 Boosts the Pneumonia Franchise; Raising PT to $19 From $11

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 17

05/14/2021

Company Report

Pages: 5

AR-501 and AR-712 Show Progress; Reiterate Buy and $11 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 18

05/11/2021

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 19

04/09/2021

Company Report

Pages: 5

Showing an Ability to Innovate and Compete With Limited Resources; Reiterate Buy Rating and $11 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Aridis Pharmaceuticals

Industry: Medical - Biomedical and Genetics

Record: 20

03/31/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party